13:53:12 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-10-31 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-06-05 X-dag ordinarie utdelning NAVA 0.00 NOK
2024-06-04 Årsstämma 2024
2024-04-30 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-01 Kvartalsrapport 2023-Q3
2023-08-11 Kvartalsrapport 2023-Q2
2023-06-02 X-dag ordinarie utdelning NAVA 0.00 NOK
2023-06-01 Årsstämma 2023
2023-05-11 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-01 Kvartalsrapport 2022-Q3
2022-08-12 Kvartalsrapport 2022-Q2
2022-06-03 X-dag ordinarie utdelning NAVA 0.00 NOK
2022-06-02 Årsstämma 2022
2022-05-10 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-13 Kvartalsrapport 2021-Q2
2021-06-04 X-dag ordinarie utdelning NAVA 0.00 NOK
2021-06-03 Årsstämma 2021
2021-05-11 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-04 X-dag ordinarie utdelning NAVA 0.00 NOK
2020-06-03 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-03-11 Extra Bolagsstämma 2020
2020-02-13 Bokslutskommuniké 2019
2019-11-01 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 X-dag ordinarie utdelning NAVA 0.00 NOK
2019-05-28 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-12-20 Extra Bolagsstämma 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-06-08 X-dag ordinarie utdelning NAVA 0.00 NOK
2018-06-07 Årsstämma 2018
2018-05-30 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-07-28 Kvartalsrapport 2017-Q2
2017-06-07 X-dag ordinarie utdelning NAVA 0.00 NOK
2017-06-06 Årsstämma 2017
2017-05-10 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2017-01-13 Extra Bolagsstämma 2017
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-06-21 X-dag ordinarie utdelning NAVA 0.00 NOK
2016-06-20 Årsstämma 2016
2016-05-11 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-10-30 Extra Bolagsstämma 2015
2015-10-30 Kvartalsrapport 2015-Q3
2015-08-21 Kvartalsrapport 2015-Q2
2015-06-09 X-dag ordinarie utdelning NAVA 0.00 NOK
2015-06-08 Årsstämma 2015
2015-04-28 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-10-31 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-06-10 Årsstämma 2014
2014-05-06 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-11-01 Kvartalsrapport 2013-Q3
2013-08-30 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-05-23 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-15 Bokslutskommuniké 2012
2012-02-10 Bokslutskommuniké 2011
2011-10-21 Kvartalsrapport 2011-Q3
2011-08-25 Kvartalsrapport 2011-Q2
2011-05-05 Kvartalsrapport 2011-Q1
2011-04-14 Årsstämma 2011
2011-02-04 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-26 Kvartalsrapport 2010-Q2
2010-05-05 Kvartalsrapport 2010-Q1
2010-03-25 Årsstämma 2010
2010-02-11 Bokslutskommuniké 2009


ListaOB Match
IndustriLäkemedel & Handel
Navamedic är ett nordiskt läkemedelsföretag som levererar läkemedel, OTC, medicinska nutritionsprodukter för sällsynta diagnoser samt medicintekniska produkter till sjukhus och apotek inom områden som exempelvis obesitas, kvinnohälsa, urologi, mage/tarm, samt smärta. Navamedic verkar i de nordiska länderna, Baltikum och Benelux men är även representerade i Storbritannien och Grekland. Bolaget etablerades 1999 med säte i Oslo.
2022-08-04 14:09:06

Oslo, 4 August 2022 - Navamedic has signed an agreement with the French pharmaceutical company Vectans Pharma, which gives Navamedic the exclusive right to market and sell an innovative and unique muco-adhesive buccal tablet for single-dose treatment of cold sores (herpes labialis) in the Nordic and Benelux regions. This entitles Navamedic to the ownership of the marketing authorizations for the product in these regions.

"This acquisition is a great example of how we can utilize our strong presence and in-depth competence in our markets to broaden our portfolio through partnerships with international pharma companies and introduce attractive products to the benefit of end-users. It is a key element of our value creation strategy to secure and increase value creation through ownership of products and exclusive marketing rights," says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.

The product is currently marketed as a prescription drug in the US and South Korea but is now in transition to becoming a non-prescription or "Over the Counter (OTC)" drug in many markets. It has already been approved as OTC drug in France and Italy and applications are currently in progress in many European countries.

Cold sores - also called fever blisters - is a common and recurring condition that affects about 20 - 40% of the population. It is caused by the herpes simplex virus and the outbreaks are often triggered by another illness, sunshine exposure, or menstrual periods. During outbreaks, the sores are contagious from the first moment of tingling and can spread from person to person by close contact.

The transfer of the marketing authorizations will take place subsequent to the OTC approval in each country. Navamedic expects the first commercial sale in the Nordics and Benelux to take place in the first half of 2024.

"We are delighted to collaborate with Navamedic and to initiate our partnership together. We firmly believe that Sitavig® has the potential to become the `best-in-disease' medicine for cold sores in the Nordic and Benelux regions, offering a new innovative treatment to patients in need. This partnership is an important step in our development plan and reinforces our international strategy", says Jérôme Théron, co-founder and CEO of Vectans Pharma".

About Sitavig®:

Sitavig® (acyclovir) is a 50mg Muco-Adhesive Buccal tablet that represents a breakthrough in the treatment of cold sores. Sitavig® is a unique single-dose treatment that is placed under the patient's lip and works by delivering a concentrated dose of acyclovir that stays localized at the site of viral replication in the mouth.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62842

E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA:

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA).

For more information, please visit www.navamedic.com

About Vectans Pharma:

"Vectans Pharma is a French pharmaceutical company with an international reach, specialized in the development of muco-adhesive drugs, and offering new therapeutic perspectives to the pharmaceutical industry. Thanks to its innovative platform, Lauriad®, our company ensures the development of new drugs and, with its international partners, the commercialization of Sitavig® and Loramyc® worldwide. Vectans Pharma delivers life-changing treatments, respectful of both humans and the environment, that improve patient access and experience around the world."

For more information about Vectans Pharma, please visit https://www.vectanspharma.com/ (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.vectanspharma.com%2F&data=05%7C01%7Cole.henrik.eriksen%40navamedic.com%7C5aa1f243cc50477aa6cd08da643104cf%7Ca5635f8e246b48e094e8806923fb2a69%7C1%7C0%7C637932458953341715%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=rj2ytK6psxj5vj10b%2BnokixJS5uClOtg1Q%2FU%2Fpt4Rp0%3D&reserved=0)